Guide
Is compounded GLP-1 medication still legal?
Short answer: yes, but in a much narrower form than in 2024 — and the FDA moved again this year.
Updated 2026-09-18 · Prices verified independently
Why you can trust this: we take payment from one company on this page — Coreage Rx — when a reader signs up through our link. It does not change the prices we print or the rubric we score against, both of which are published in full on how we rate. Read our full disclosure.
This is the question we are asked more than any other, and the honest answer has changed three times in two years. Here is where it stands today.
Compounded GLP-1s are no longer the freely marketed product they were in 2024. They remain legal in a narrower form, and the rules changed again in 2026.
How we got here
| When | What happened |
|---|---|
| December 2024 | FDA declared the tirzepatide shortage resolved. |
| February 2025 | FDA declared the semaglutide shortage resolved, ending the shortage-based pathway that allowed large-scale compounding. |
| 16 September 2025 | FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications. |
| 1 April 2026 | FDA reminded compounders that specific conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B. |
| 30 April 2026 | FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, saying there is no clinical need for compounded versions. |
| 30 July 2026 | Comment period on that proposal closed after an extension. |
What that means if you are buying today
- A 503A pharmacy may still compound a GLP-1 for an individual patient when there is a documented, patient-specific clinical reason — for example a required dose or formulation that the approved product does not provide.
- Routinely marketed, off-the-shelf compounded GLP-1 sold like a consumer product is not permitted under that framework.
- If the 503B Bulks List proposal is finalised, outsourcing facilities would lose the pathway they have been using to produce these drugs in volume.
- Compounded versions are not FDA-approved. The agency does not review them for safety, effectiveness or manufacturing quality the way it reviews Zepbound or Wegovy.
The part that matters most
Compounded versions are not FDA-approved. The agency has not reviewed them for safety, effectiveness or manufacturing quality the way it reviewed Zepbound and Wegovy. That is not the same as saying they are unsafe — but it is a genuine difference, and any review site that glosses over it is selling you something.
Questions worth asking a provider
- Which pharmacy fills this, and is it a 503A or 503B facility?
- What is the patient-specific clinical reason for compounding in my case?
- What happens to my prescription if the 503B Bulks List proposal is finalised?
- Can you move me to an FDA-approved product without restarting, and at what cost?
- Is the price I have been quoted the ongoing price, or an introductory rate?
Providers that answer those five questions plainly are the ones worth your money. Our reviews note which ones do.
If you would rather avoid the question entirely
Branded medication removes the ambiguity. Through LillyDirect self-pay, single-dose Zepbound vials at 5 mg, 7.5 mg and 10 mg have been listed at $499/month, with lower starting doses nearer $299-$349. Through NovoCare, Wegovy has been offered at $199/month for the first two fills through 31 December 2026, then $349/month for 0.25-2.4 mg doses. The oral form is listed between $149 and $299/month by dose. Ro works exclusively with approved products, and LifeMD and Mochi will pursue insurance coverage on your behalf.
Read next
- Tirzepatide vs semaglutide
One trial put them head to head. The result was not close — but the cheaper drug still wins for some people.
- The best tirzepatide providers in 2026
12 programmes compared on what you actually pay in month two — not the teaser rate. Coreage Rx comes first.
- Ro tirzepatide review
Branded medication with insurance help. We checked the advertised price against what you are actually billed. True cost: $448 a month.
- Coreage Rx tirzepatide review
Best overall on true monthly cost. We checked the advertised price against what you are actually billed. True cost: $199 a month.
- What you actually pay
Six pricing tricks that turn a $99 advert into a $298 statement, and how to check before you hand over a card.